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Canine models of severe haemophilia resemble their human equivalents both regarding
clinical bleeding phenotype and response to treatment. Therefore pre-clinical studies in hae-
mophilia dogs have allowed researchers to make valuable translational predictions regard-
ing the potency and efficacy of new anti-haemophilia drugs (AHDs) in humans. To refine in
vivo experiments and reduce number of animals, such translational studies are ideally pre-
ceded by in vitro prediction of compound efficacy using a plasma based global coagulation
method. One such widely used method is the thrombin generation test (TGT). Unfortunately,
commercially available TGTs are incapable of distinguishing between normal and haemo-
philia canine plasma, and therefore in vitro prediction using TGT has so far not been possi-
ble in canine plasma material.
Aim
Establish a modified TGT capable of: 1) distinguishing between normal and haemophilia
canine plasma, 2) monitoring correlation between canine plasma levels of coagulation factor
VIII (FVIII) and IX (FIX) and thrombin generation, 3) assessing for agreement between com-
pound activity and thrombin generation in ex vivo samples.
Methods
A modified TGT assay was established where coagulation was triggered using a commer-
cially available activated partial thromboplastin time reagent.
Results
With the modified TGT a significant difference was observed in thrombin generation
between normal and haemophilia canine plasma. A dose dependent thrombin generation
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was observed when assessing haemophilia A and B plasma spiked with dilution series of
FVIII and FIX, respectively. Correlation between FVIII activity and thrombin generation was
observed when analyzing samples from haemophilia A dogs dosed with canine FVIII. Limit
of detection was 0.1% (v/v) FVIII or FIX.
Conclusion
A novel modified TGT suitable for monitoring and prediction of replacement therapy efficacy
in plasma from haemophilia A and B dogs was established.
Introduction
Haemophilia A and B (HA and HB, respectively) are severe bleeding disorders caused by
mutations in the genes encoding coagulation factor VIII (FVIII) or coagulation factor IX
(FIX), respectively. Patients present with low or undetectable plasma activities of FVIII or FIX,
leading to a decreased capacity to form thrombin. Clinically this decreased capacity manifests
as spontaneous bleeding episodes affecting the joints, muscles and soft tissue[1]. Disease sever-
ity, typically based upon residual plasma activity of FVIII or FIX, is classified as mild (<40%),
moderate (<5%) or severe (<1%) [2]. The classification of HA patients based upon residual
factor activity is well-documented, especially for classification of HA patients with a clinically
severe bleeding phenotype[3]. The standard treatment regimen for haemophilia is prophylac-
tic or on-demand replacement therapy with FVIII or FIX, but treatment is complicated by a
risk of developing inhibitory antibodies towards the administered coagulation factors. For
FVIII replacement therapy, approximately 30% of patients develop inhibitors against FVIII,
and much effort has been and is still put into development of anti-haemophilic drugs (AHD)
that bypass FVIII and FIX in the coagulation system[4].
Globally different treatment protocols are used for treating haemophilia[5], where some
regimens aim at obtaining a certain factor trough level, and others on tailoring the treatment
according to individual bleeding phenotype. It is however difficult, to predict the exact dose of
FVIII or FIX needed to stop or prevent bleeding episodes in individual patients. This makes
optimizing haemophilia treatment based on individual needs challenging[6], and improved
methodologies are needed to address these issues. Evidence is accumulating to support the
hypothesis that the thrombin generation test (TGT) may reflect the bleeding risk of patients
with coagulation disorders[7]. By utilizing the TGT researchers have reported correlations
between TGT parameters and the clinical bleeding phenotype as well as response to treatment
in human HA patients [8, 9].
Haemophilia A and B dogs are excellent models of haemophilia, as clinical bleeding pheno-
type and response to treatment resembles their human equivalents[10, 11] and canine models
of haemophilia have served as valuable tools for assessing the potency of AHD for decades[11].
As in humans, it is unpredictable how much FVIIa, FVIII or FIX is needed to stop or prevent
bleeding episodes in individual dogs, and new tools for monitoring treatment in these dogs is
therefore desirable for monitoring of treatment efficacy. In translational studies, where AHDs
were tested in animal models, the TGT method proved useful for testing and qualification of
new AHD candidates[12, 13]. However the standard TGT method is not sensitive to the levels
of FVIII and FIX in the plasma of dogs, and is therefore not able to distinguish between normal
and HA or HB dogs.
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Thus, to rationally predict treatment efficacy in canine models of haemophilia both in vitro
and in vivo we aimed to develop a canine optimized TGT. The assay should have the following
attributes: 1) distinguish between normal and haemophilia dogs, 2) monitor correlation
between plasma FVIII/FIX in vitro activity and thrombin generation and 3) assess for correla-
tion between FVIII activity and thrombin generation in ex vivo samples.
Materials and methods
Ethical approval
All protocols carried out at University of North Carolina, Chapel Hill, NC, US were in accor-
dance with institutional guidelines and approved by the Institutional Animal Care and Use
Committee at the University of North Carolina at Chapel Hill (Approval number 14–111),
All studies were approved by Novo Nordisk A/S internal Ethical Review Committee.
Husbandry, diet, housing and care of dogs at University of Chapel Hill,
Francis Owen Blood Research Lab (FOBRL)
All of the dogs in this study were produced and maintained at the FOBRL at the University of
North Carolina at Chapel Hill. The FOBRL is a specialized facility that houses strains of dogs
with hemophilia A, hemophilia B, von Willebrand disease (VWD), combined hemophilia A/
VWD, FVII deficiency, and normal blood donor dogs. Dogs are housed on indoor/outdoor
runs, whereby the indoor portion provides conditioned space. In general, dogs are housed in
pairs for socialization. This space for all animals meets or exceeds USDA and NIH require-
ments and AAALAC recommendations. In addition, the dogs are allowed into fenced play
yards for socialization and enrichment. Two exam/procedure rooms are used for all examina-
tions, clinical treatments and transfusions, blood collection and plasma banking, dental pro-
phylaxis, and experimental procedures. Normal dogs are maintained as a “walking blood
bank” for canine replacement products. Some of these animals are Universal donors to provide
whole blood for direct transfusion in emergency cases. Clinical diagnostic equipment (e.g.,
microscopes, SCIL cell counter, otoscope, stethoscopes, refractometer, thermometers, hemo-
globinometer) is on site. The animals are fed once or twice daily and their housing areas are
cleaned at least once daily. Most of the dogs in the colony are fed solid food but some have spe-
cial needs and require different source of nutrition. Nutrition is discussed regularly with the
attending veterinarians and any changes are made accordingly. The dogs in this study have
severe hemophilia. The bleeding phenotype is severe, spontaneous and stochastic and without
prompt treatment can be crippling or fatal. All dogs are checked at least twice daily, 7 days a
week for any health problem with a particular emphasis on the emergence of a bleeding event.
This professional staff and registered veterinary technicians share call 24/7 for emergencies.
Animal care at the FOBRL is designed and supervised by the veterinary staff of the Division of
Laboratory Animal Medicine. Several of the members of this team have cared for these dogs
for over 20 to 30 years.
Monitoring of dogs used for ex vivo study
The dogs in this study had blood samples drawn by venipuncture. After sampling, they were
monitored until hemostasis was confirmed, usually 10 to 15 minutes. Any issues related to
pain or distress are discussed with the attending veterinarian. The dogs in this study only had
blood samples drawn by venipuncture so any related pain or distress was minimal and very
brief.
No dogs were euthanized for this study. All dogs were returned to the colony.
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Haemostatically normal and haemophilic dogs
Blood samples were collected from normal healthy Hound Mix dogs at FOBRL, UNC, Chapel
Hill, NC.
Blood samples were collected from HA and HB dogs from the dog colony at FOBRL. The
underlying genetic defect of the severe HA dog colony at Chapel Hill is due to an inversion in
intron 22 of the FVIII gene. All dogs carrying this mutation present with undetectable levels of
FVIII based upon activity measures (<0.3% FVIII activity)[14, 15]. The FVIII activity in all
plasma samples drawn from HA dogs was measured using a chromogenic FVIII activity assay
(COAMATIC FACTOR VIII, Chromogenix, Instrumentation Laboratory Company, Bedford,
MA, US) according to manufacturer’s instructions, with normal canine plasma diluted in HA
plasma as calibrator. The limit of detection of this method is 0.3% FVIII activity. Unless stated
otherwise, the FVIII activity in the HA plasma samples were below the detection level of the
assay.
The HB dog colony disease is caused by a point mutation in the FIX encoding gene, which
affects the active site of the FIX protein, giving rise to undetectable plasma levels of FIX [15,
16].
Blood drawing and plasma preparation
Blood samples were collected from at least 12h fasted dogs. Blood samples were drawn from
the cephalic vein in 3.2% sodium citrate (1 part 3.2% sodium citrate and 9 parts blood). Plasma
was obtained by double centrifugation of whole blood at 2200G for 15 min followed by centri-
fugation of plasma at 2200G for 7 min at 4˚C. Aliquots were frozen at -80˚C 5 minutes after
aliquotation.
Establishment of plasma pools
Three separate normal canine plasma pools were established from healthy hound mix dogs at
FOBRL. The pools are denoted normal pool I, II and III.
Two HA and one HB canine plasma pools were established from five individual HA and
HB dogs (referred to as HA pool I and II and HB pool).
A HA and HB canine plasma pool with 0.1% (v/v) normal plasma was prepared by addition
of 0.1% (v/v) normal plasma to the HA or HB plasma pool (referred to as 0.1% norm. in HA
and HB).
Recombinant canine B-domain deleted FVIII (rcBDDFVIII)
Recombinant canine B-domain deleted FVIII (rcBDDFVIII) was produced as described by
Sabatino et al.[17].
Inhibitory capacity of an anti canine-FVIII polyclonal antibody (Anti cFVIII
PAb)
A commercial available inhibitory polyclonal sheep anti cFVIII antibody SAC8C-IG (lot:
Ig1386R4) (Affinity Biologicals, Ancaster, Ontario, Canada) was used throughout the experi-
ments. The inhibitory capacity of this antibody was tested by incubating normal pool III with
0.1 mg/mL anti cFVIII PAb for 30 minutes at room temperature with mild agitation. The
FVIII activity in this preparation was subsequently analyzed using a chromogenic FVIII activ-
ity assay (COATEST SP4 FVIII, Chromogenix, Instrumentation Laboratory Company, Bed-
ford, MA, US) according to manufacturer’s instructions, but with normal pool III diluted in
HA pool II as calibrator. All samples were run in duplicate.
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Thrombin generation test using the Calibrated Automated Thrombogram
(CAT) method
Thrombin generation was measured using the CAT method, essentially as described by Hem-
ker et al., but using half the volume of reagent and plasma [18]. Ten μL trigger solution PPP
reagent (5 pM rhTF final in asssay) or PPP reagent low (1 pM rhTF final in assay)(Thrombino-
scope BV), or 10 μL Thrombin calibrator (Thrombinoscope BV) was added to separate wells
in Immulon 2HB 96-well round-bottom microtiter plates (Thermo Scientific, Waltham, MA,
USA). Forty μL plasma, thawed at 37˚C for 5 mins, was added to each well, and the plate was
incubated for 10 mins at 37˚C in a Fluoroskan Ascent fluorometer (Thermo Scientific). For-
ty μL Fluo Substrate (Z-gly-gly-arg-AMC, Thrombinoscope BV) was added to 1600 μL Fluo
Buffer (Thrombinoscope BV) pre-warmed to 37˚C, and 10 μL of this solution was automati-
cally dispensed to each well using the fluorometer. The calcium source in this setup is the Fluo
Buffer, which contains 100 mM CaCl2). A final assay concentration of 16.6 mM CaCl2 is there-
fore obtained. Thrombograms were obtained using the accompanying Thrombinoscope soft-
ware (Thrombinoscope BV). From the thrombograms the following thrombin generation
parameters were automatically calculated: lag time, endogenous thrombin potential (ETP),
peak thrombin generation and time to peak (TTP).
Assessment of the thrombin formation in canine plasma samples using
the standard calibrated automated thrombogram (CAT) method
Normal pool III, normal pool III incubated with 0.1 mg/ml anti cFVIII PAb and HA pool II
were analyzed using the standard CAT method, with PPP reagent and PPP reagent low (5 and
1 pM rhTF final dilution in assay, respectively). All samples were analyzed in quadruplicate.
Thrombin generation test using the canine optimized TGT
Twenty μL BSA5-buffer (20 mM HEPES, 140 nM NaCl (Merck KGaA, Darmstadt, Germany),
5 g/L bovine serum albumin (Sigma Life Science, St. Louis, MO, US), pH 7.35) or 20 μL Thro-
mbin calibrator was added to separate wells in Immulon 2HB 96-well microtiter plates. Seven-
ty μL test plasma was added to each well. Forty-four μL Fluo Substrate were added to 1600 μL
37˚C Fluo Buffer, and the ampoule was whirl-mixed for 5 sec. Immediately before initiating
the experiments 230 μL Actin FS (Siemens Healthcare Diagnostics Product GmbH, Marburg,
Germany) were added to the above mentioned solution, and the solution was whirl-mixed for
5 seconds. Subsequently this solution was loaded onto the apparatus’ pump, and 30 μL of this
solution was automatically dispensed to each well. Thrombin generation parameters were
obtained as mentioned above.
Using the canine optimized TGT a final assay concentration of 21.3 mM CaCl2 was
obtained.
Analysis of canine plasma material using the canine optimized TGT
Assessment of the capability of the canine optimized TGT to discriminate between nor-
mal and HA canine plasma. Plasma samples from five healthy dogs, five HA dogs, normal
pool II and the HA pool were analysed using the canine optimized TGT.
To asses if residual amounts of FVIII, below the detection limit of the chromogenic FVIII
activity assay, in individual HA plasma samples gave rise to variation in thrombin generation,
plasma samples from five HA dogs were incubated with 0.1 mg/mL anti cFVIII PAb or PAb
buffer for 30 min at RT with mild agitation, and were subsequently analyzed using the canine
optimized TGT.
Coagulation factor VIII/IX sensitive thrombin generation test for canine plasma
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To confirm the capacity of the anti cFVIII PAb to inhibit thrombin formation in plasma
normal pool II was analyzed in the presence and absence of 0.1 mg/mL anti FVIII PAb. The
HA canine plasma pool was used as comparator.
Assessment of cFVIII and cFIX dose dependent thrombin generation. Normal pool I
was diluted in HA pool to 100, 50, 25, 10, 5, 2.5, 1, 0.5 and 0.1% (v/v) normal in HA canine
plasma pool, and underwent analysis using the canine optimized TGT. HA pool was spiked
with rcBDDFVIII to 1, 0.5, 0.25, 0.1, 0.05, 0.025, 0.01, 0.005 and 0.001 U/mL final rcBDDFVIII
activity. The spiked plasmas were analysed using the canine optimized TGT.
Normal pool II was diluted in the HB plasma pool to 100, 50, 25, 10, 5, 2.5, 1, 0.5 and 0.1%
(v/v) normal in HB canine plasma pool, and underwent analysis using the canine optimized
TGT.
Assessment of imprecision of the canine optimized TGT. Intra assay imprecision esti-
mates were determined by analysis of 20 replicates in the same analytical run of: normal pool
II, 0.1% norm. in HA, 0.1% norm. in HB, HA pool and HB pool.
Inter assay imprecision estimates were determined by analysis of duplicates of normal pool
I, 0.1% norm. in HA and 0.1% norm. in HB stock over seven separate runs.
Assessment of the applicability of the canine optimized TGT to measure thrombin gen-
eration in ex vivo samples. Six HA dogs were dosed with rcBDDFVIII or normal canine
plasma to achieve FVIII activities of 3, 10 and 100% of normal. Samples were collected 15 and
30 minutes after each dosing as described previously. Between each dosing, a washout period
before next administration, lasting at least 14 days, was realized.
The FVIII activity of each sample was measured using a chromogenic FVIII activity assay
(COAMATIC FACTOR VIII).
All samples were analyzed using the canine optimized TGT.
Statistical analysis
All statistical analyses were carried out using GraphPad Prism 6.05 for Windows (GraphPad
Software, La Jolla California USA, www.graphpad.com).
Statistical significance assumed for p<0.05.
Differences in peak thrombin generation between normal pooled canine plasma and nor-
mal pooled plasma incubated with anti cFVIII PAb analyzed using TGT with 1 and 5 pM TF
were analyzed using a Mann-Whitney test (Two-tailed P-value given). The same analysis was
carried out when normal pooled canine plasma and HA pooled canine plasma were analyzed
under identical conditions.
Difference in peak thrombin generation between a group of five normal dogs and a group
of five HA dogs was assessed using the Mann-Whitney test.
When the inhibitory capacity of the anti cFVIII PAb was assessed using the canine opti-
mized TGT, a paired t-test (two-tailed) was used for comparison of peak thrombin genera-
tions. The intra-assay CV% for HA plasma was used for the analysis.
Dose dependency between thrombin generation parameters and FVIII or FIX activity was
analyzed by plotting raw or transformed thrombin generation parameters against raw or trans-
formed factor activities. The linear associations were calculated as the squared Pearson correla-
tion coefficient r2.
When assessing if residual amounts of cFVIII contributed to thrombin generation in HA
plasma a multiple paired t-test was used. Intra assay CV% for 0.1% normal in HA was used for
this analysis.
Intra-assay imprecision estimates were determined based on 20 replicates of samples. Intra-
assay CV%s were divided by 2½ to reflect intra-assay imprecision of double determinations.
Coagulation factor VIII/IX sensitive thrombin generation test for canine plasma
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Acceptability criteria are based upon reported imprecision estimates of human plasma sam-
ples analyzed using TGTs, and are presented in S1 Table.
The correlation between log10 transformed FVIII activity plotted against peak thrombin
generation was computed as Pearson correlation coefficients (r), given with two-tailed P val-
ues. Slopes from plots of log10 transformed FVIII activity against peak thrombin generation
(nM) were compared using a one-way ANOVA, and Bartlett’s test was used to test for equal
variance among the plots.
Limit of detection for the assay was assessed by comparing CAT parameters obtained from
analysis of 20 replicates of HA plasma with 20 replicates of 0.1% (v/v) normal canine plasma in
HA or HB plasma using a paired t-test.
Results
Inhibitory capacity of an anti-canine-FVIII polyclonal antibody (anti cFVIII
PAb)
A residual FVIII activity of 1.3% was observed when the normal canine plasma pool II incu-
bated with 0.1 mg/mL anti cFVIII PAb was analyzed using the chromogenic FVIII activity
assay.
Assessment of thrombin formation in canine plasma samples using the
standard CAT method
A slightly higher thrombin generation (peak thrombin generation) was observed for the nor-
mal plasma pool compared with the normal plasma pool incubated with anti cFVIII PAb at
both TF concentrations (5 and 1 pM) (Fig 1A) (p>0.05). A higher peak thrombin generation
was also observed when normal plasma pool was compared with a HA plasma pool in the
CAT setup using 5 and 1 pM TF as trigger (Fig 1B) (p>0.05).
Analysis of canine plasma material using the canine optimized TGT
Assessment of the capability of the canine optimized TGT to discriminate between nor-
mal and HA canine plasma. Peak thrombin activities spanning 200–230 nM thrombin were
observed for the normal dogs and the normal pool, whereas HA plasma samples gave rise to
peak thrombin activities spanning 5–25 nM thrombin. Both lag time and TTP were prolonged
for the HA samples compared with the normal, and the ETP of the HA samples was decreased
Fig 1. Analysis of normal and haemophilia A canine plasma pools using the CAT method. Thrombin generation was
monitored using the standard CAT method, and was initiated using tissue factor at 5 and 1 pM (PPP and PPPlow reagent,
respectively). A) Normal plasma pool II was analyzed in the presence and absence of anti cFVIII PAb. B) Normal plasma pool II
and HA plasma pool were analyzed. Thrombograms represent mean of quadruplicates. Y-axis depicts thrombin generation in nM,
x-axis depicts time in minutes. All experiments were carried out in one run, and the normal plasma pool II results in A) and B) are
identical.
https://doi.org/10.1371/journal.pone.0175030.g001
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as well (Fig 2). A statistically significant difference was observed in the peak thrombin genera-
tions between normal and HA canine plasma (p<0.05).
It was tested if residual amounts of FVIII gave rise to inter-individual variation in thrombin
generation in HA dogs. As mentioned previously, all plasma samples collected are from severe
HA dogs, and present with FVIII activity levels below 0.3%, as judged by chromogenic FVIII
activity analysis (COAMATIC FACTOR VIII). No significant difference in peak thrombin
generation was observed between individual canine HA samples in the presence or absence of
0.1 mg/mL anti cFVIII PAb (p>0.05) (Fig 3).
Fig 2. Analysis of normal and HA plasma using the canine optimized TGT. Plasma samples from five healthy dogs, five HA
dogs, a normal canine plasma pool and a HA canine plasma pool were analyzed. A) Thrombograms represent mean of double
determinations. Y-axis depicts thrombin generation in nM, x-axis depicts time in minutes. B) Bars represent mean peak thrombin
generation in nM, and error bars represent range of double determinations. Y-axis depicts peak thrombin generation in nM, and x-
axis depicts samples.
https://doi.org/10.1371/journal.pone.0175030.g002
Fig 3. Analysis of plasma samples from five individual HA dogs using the canine optimized TGT. Bars represent mean of
double determinations, and error bars represent range. Light blue bars represent analysis of plasma samples in the presence of
buffer, and dark blue bars represent analysis of plasma samples in the presence of 0.1 mg/mL anti cFVIII PAb. The buffer sample
from P16 represents a single determination, as one of the double determinations failed. X-axis represents dog identifier, and y-
axis represents peak thrombin generation in nM thrombin.
https://doi.org/10.1371/journal.pone.0175030.g003
Coagulation factor VIII/IX sensitive thrombin generation test for canine plasma
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When confirming the capacity of the anti cFVIII PAb to inhibit thrombin formation in
plasma a statistically significant decreased thrombin generation was observed when normal
pool was pre-incubated with 0.1 mg/mL anti cFVIII PAb. No difference was observed between
peak thrombin generation of normal pool incubated with anti cFVIII PAb and peak thrombin
generation of the HA pool (p>0.05) (S1 Fig).
Assessment of the cFVIII and cFIX dose dependent thrombin generation. cFVIII dose
dependent thrombin generation was observed when a dilution series of normal pool I span-
ning 0–100% (v/v) normal in HA pool or rcBDDFVIII (0-1U/mL) spiked in HA pool were
analyzed using the canine optimized TGT (Fig 4). Dose dependency was observed for all four
CAT parameters, (r2 >0.98, p<0.05 for all correlations). (Fig 4, S2 Fig and S3 Fig)
Assay sensitivity towards cFIX was assessed by diluting normal pool in a HB plasma pool
(Fig 5). A statistical significant dose dependent relationship between dilution degree and
thrombin generation was observed for all four CAT parameters (r2 >0.96, p<0.05 for all corre-
lations) (Fig 5 and S4 Fig).
Assessment of imprecision of the canine optimized TGT. Thrombograms from intra-
assay imprecision runs are presented in Fig 6, and imprecision estimates are presented in
Table 1. Inter-assay imprecision estimates are given in Table 2. The intra- and inter-assay
imprecision of the assay is acceptable according to the criteria established in the statistical sec-
tion and S1 Table.
Limit of detection. From imprecision data it was demonstrated that the ETP, Peak
thrombin generation and TTP parameters were significantly different between deficient
plasma and 0.1% (v/v) normal in deficient plasmas (p<0.01). Limit of detection of the assay is
therefore set to0.1% (v/v) normal in HA or HB plasma.
Fig 4. Analysis of normal canine plasma pool and rcBDDFVIII dilutions in haemophilia A canine plasma pool. Samples
were analyzed using the canine optimized thrombin generation test. A) Dilutions spanning 0–100% normal in HA plasma pool (v/v)
were analyzed. 100% represents undiluted normal pool and 0% represents undiluted HA plasma pool. Normal pool I was utilized.
B) The HA plasma pool was spiked with 0–1 U/mL rcBDDFVIII. Zero U/mL represents HA plasma. Thrombograms represent
mean of double determinations. Y-axis depicts thrombin generation in nM, x-axis depicts time in minutes. C) Correlation analysis
of peak thrombin generation versus dilution of normal canine plasma pool in HA pool from panel A. D) Correlation analysis of peak
thrombin generation versus rcBDDFVIII activity spiked into the HA canine plasma pool from panel B. The log10 transformed x-
axes in panel C and D represent plasma dilutions or rcBDDFVIII activity, and y-axes represent peak thrombin generation in nM.
Points represent mean of double determinations, lines represent linear regression analysis.
https://doi.org/10.1371/journal.pone.0175030.g004
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Assessment of the applicability of the canine optimized TGT to measure thrombin gen-
eration in ex vivo samples. Correlations between FVIII activity measurement and peak
thrombin generation from six individual dogs are depicted in Fig 7. Statistically significant
correlations were observed between log10 transformed FVIII activities and peak thrombin
Fig 5. Analysis of normal canine plasma pool dilutions in haemophilia B canine plasma pool. Samples were analyzed
using the canine optimized thrombin generation test. A) Dilutions spanning 0–100% normal diluted in HB plasma pool (v/v)
were analyzed. 100% represents undiluted normal plasma pool, and 0% represents undiluted HB pool. Thrombograms
represent mean of double determinations. Y-axis depicts thrombin generation in nM, x-axis depicts time in minutes. B)
Correlation analysis of peak thrombin generation versus dilution of normal canine plasma pool in HB pool from panel A. The
log10 transformed x-axis represents plasma dilutions, and the log10 transformed y-axis represents peak thrombin generation
in nM. Points represent mean of double determinations, lines represent linear regression analysis.
https://doi.org/10.1371/journal.pone.0175030.g005
Fig 6. Thrombograms from imprecision estimation of the canine optimized TGT. Twenty replicates of each sample were
analyzed per run. Each thrombogram represents a single determination. The following samples were analyzed: A) normal canine
plasma pool II, B) normal canine plasma pool II diluted to 0.1% (v/v) in haemophilia A (HA) plasma pool and the HA plasma pool,
C) normal canine plasma pool II diluted to 0.1% (v/v) in haemophilia B (HB) plasma pool and the HB plasma pool. Y-axis depicts
thrombin generation in nM and x-axis depicts time in minutes.
https://doi.org/10.1371/journal.pone.0175030.g006
Coagulation factor VIII/IX sensitive thrombin generation test for canine plasma
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generation for all six dogs. Pearson correlation coefficients (r) spanned 0.90–0.98, all with P-
values<0.0001. Slopes from the plots of log10 transformed FVIII activity against peak thrombin
generation were compared, and were statistically significantly different (p<0.0001, one-way
ANOVA). Equal variance of the calculated slopes were confirmed (p = 0.47, Bartlett’s test).
All raw data is available in S1 File.
Discussion
With the canine optimized TGT a clear differentiation between normal and HA canine plasma
was possible (Fig 2). Inter-individual differences in thrombin generation potential were
observed both for individual normal dogs and individual HA dogs, which has also been
observed among healthy individuals and HA patients [18, 19]. It was ruled out that the inter-
individual variability in the thrombin generation potential observed in five individual HA
dogs was related to residual amounts of FVIII in the plasma samples, by analysing samples in
the presence and absence of an anti cFVIII PAb (Fig 3). The present assay is dose dependently
sensitive to both the FVIII and FIX levels in canine plasma, as dilutions of normal in deficient
plasma and spike with rcBDDFVIII in HA plasma gave rise to dose dependent thrombin gen-
eration (Figs 4 and 5 and S2–S4 Figs).
The limit of detection of the assay was at least 0.1% FVIII and 0.1% FIX (Fig 6) and intra-
and inter assay imprecision analysis revealed acceptable CV percentages both for normal
canine plasma and for 0.1% (v/v) normal in deficient plasmas (Table 1 and Table 2).
The applicability of the assay for analysis of thrombin generation ex vivo was assessed by
analysis of plasma samples collected from six severe HA dogs treated with rcBDDFVIII or
Table 1. Intra-assay imprecision estimates.
Normal pool II 0.1% norm in HA 0.1% norm in HB HA pool
Mean CV% Mean CV% Mean CV% Mean CV%
Lag time 5 3.2 16.9 2.6 9.2 5.2 16.8 3.7
ETP 700.6 1.9 175.6 5.7 308.9 3.8 46.4 16.5
Peak 201.2 2.5 19.8 8.1 41.4 4.0 2.2 14.9
Time to peak 6.7 2.5 21.9 2.8 13.2 4.3 26.1 4.4
The table presents intra-assay imprecision estimates of double determinations based upon analysis of 20 replicates of a normal canine plasma pool, 0.1%
(v/v) normal canine plasma pool in a haemophilia A (HA) canine plasma pool, 0.1% (v/v) normal canine plasma pool in a haemophilia B (HB) canine plasma
pool and a HA canine plasma pool. Values are given in Lag time; min, ETP; nMmin, Peak; nM, time to peak; min. CV%; coefficient of variation given as
percentage.
https://doi.org/10.1371/journal.pone.0175030.t001
Table 2. Inter-assay imprecision estimates.
Normal pool I 0.1% norm in HA 0.1% norm in HB
Mean CV% Mean CV% Mean CV%
Lag time 4.8 8.6 14.6 9.2 13.1 7.6
ETP 683.7 4.5 268.5 9.4 240.9 13
Peak 167.4 7.7 32 13.2 33.3 15.3
Time to peak 6.9 8 19.2 6.8 17.4 7.1
The table presents inter-assay imprecision estimates based upon analysis of duplicates of a normal canine plasma pool, 0.1% (v/v) normal canine plasma
pool in a haemophilia A (HA) canine plasma pool and 0.1% (v/v) normal canine plasma pool in a haemophilia B (HB) canine plasma pool in seven
independent runs. Values are given in Lag time; min, ETP; nM*min, Peak; nM, time to peak; min. CV%; coefficient of variation given as percentage.
https://doi.org/10.1371/journal.pone.0175030.t002
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Fig 7. Correlation between FVIII activity and thrombin generation in ex vivo plasma samples. Correlation analysis
between FVIII activities and peak thrombin generation of samples from six individual haemophilia A dogs dosed with varying
levels of rcBDDFVIII and normal canine plasma on several occasions. Each point represents mean of double determinations,
and the line represents linear regression analysis of the plots. Y-axes depict peak thrombin generation in nM thrombin, and
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normal canine plasma. Correlations between measured plasma FVIII activity and peak throm-
bin generation were observed for all six dogs (Fig 7). This agreement justifies utilization of the
assay both for in vitro and ex vivo assessment of FVIII compound efficacy in dogs.
Within the field of haemophilia research TGT is widely used for in vitro and ex vivo assess-
ment of drug efficacy in animal models of haemophilia[12, 20]. Typically thrombin generation
is triggered by activation of the extrinsic pathway of coagulation with rhTF. However, when
we analyzed plasma samples from normal and severe HA dogs using rhTF activation no usable
difference in thrombin generation was observed (Fig 1). Therefore we developed a canine opti-
mized TGT, where thrombin generation was triggered via the intrinsic pathway of coagulation
using the APTT reagent Actin FS. Actin FS was selected as trigger based upon its synthetic and
well defined composition, supposedly assuring less lot-to-lot variation compared with other
APTT reagents where purified natural sources e.g. rabbit brain extract are part of the reagent.
During the ex vivo studies we observed a difference in response to FVIII or plasma treat-
ment measured as peak thrombin generation among the six HA dogs (Fig 7). It was evident
that the correlation between measured FVIII activity and peak thrombin generation differed
between the dogs and this even though all six dogs carried the same F8 mutation. These obser-
vations raise the question whether the assay would be suitable for individualization of FVIII
treatment, and if the variability in thrombin generation response to treatment correlates with
clinical response to treatment. Further studies are needed to answer these questions.
When measuring baseline thrombin generation potential in five individual dogs, inter-indi-
vidual differences were observed in their thrombin generation capacity (Fig 3). All dogs pre-
sented with undetectable FVIII activity leves (<0.3% in Chromogenic assay), and carry the
same F8 mutation. Whether or not the inter-individual variability in thrombin generation
capacity relates to the clinical bleeding phenotype remains unknown, and warrants further
studies.
Compared with other global coagulation methods, e.g. thromboelastography, where freshly
drawn whole blood is required, the present method excels as it allows high capacity measure-
ment of frozen plasma samples (30+ samples/run). This renders the method suitable for larger
pre-clinical studies, which otherwise would be more laborious and time consuming.
Conclusion
In conclusion we established a TGT highly sensitive to the levels of FVIII and FIX in canine
plasma, which allowed us to distinguish between normal and haemophilia dogs. Clear dose
dependent correlations were observed between factor activities and thrombin generation
parameters, and a solid agreement was observed between in vitro and ex vivo efficacy of FVIII.
Imprecision estimation of the assay revealed a robust assay that allows reliable monitoring of
thrombin generation in plasma from haemophilia dogs.
Supporting information
S1 Fig. Analysis of a normal plasma pool +/- anti canine FVIII PAb and HA pool. Normal
canine plasma pool was analyzed using the canine optimized TGT in the presence and absence
of anti cFVIII PAb, HA plasma pool was included as a control. All samples were analyzed in
duplicate, and thrombograms represent mean of double determinations. Y-axis depicts
the log10 transformed x-axes depict FVIII activity given as percentage of FVIII activity in a normal canine plasma pool. IDs
represent the identifiers for each dog, r represents Pearson correlation coefficient, and P represents two-tailed P values.
https://doi.org/10.1371/journal.pone.0175030.g007
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thrombin generation in nM, x-axis depicts time in minutes.
(TIF)
S2 Fig. Correlation analysis between CAT parameters and normal plasma in HA plasma
dilutions. Correlation analysis of calibrated automated thrombogram (CAT) parameters
obtained from analysis of normal canine plasma pool diluted in haemophilia A plasma pool,
versus dilution of normal canine plasma pool in HA canine plasma pool. Points represent
mean of double determinations, lines represent linear regression analysis. The log10 trans-
formed x-axes represent plasma dilutions, and y-axes represent CAT parameters. ETP; Endog-
enous Thrombin Potential.
(TIF)
S3 Fig. Correlation analysis between CAT parameters and rcBDDFVIII activity in HA
plasma. Correlation analysis of calibrated automated thrombogram (CAT) parameters obtained
from analysis of HA canine plasma pool spiked with rcBDDDFVIII, versus rcBDDFVIII activity
spiked into the HA canine plasma pool. Points represent mean of double determinations, lines
represent linear regression analysis. The log10 transformed x-axes represent U/mL rcBDDFVIII
in HA plasma, and y-axes represent CAT parameters. ETP; Endogenous Thrombin Potential.
(TIF)
S4 Fig. Correlation analysis between CAT parameters and normal plasma in haemophilia
B plasma dilutions. Correlation analysis of calibrated automated thrombogram (CAT)
parameters obtained from analysis of normal canine plasma pool diluted in haemophilia B
(HB) plasma pool, versus dilution of normal canine plasma pool in HB canine plasma pool.
Points represent mean of double determinations, lines represent linear regression analysis.
The log10 transformed x-axes represent plasma dilutions, and y-axes represent CAT parame-
ters (log10 transformed y-axes for ETP). ETP; Endogenous Thrombin Potential.
(TIF)
S1 File. Raw data for all figures. In this compressed file all raw data is available in excel for-
mat. Data is sorted according to figure.
(ZIP)
S1 Table. Acceptability criteria for imprecision estimates. Lag; Lag time, ETP; endogenous
thrombin potential, Peak; peak thrombin generation, TTP; time to peak.

and # indicate that
the criteria were established from Spronk et al [1]. or Waters et al. [2] respectively.
(DOCX)
Acknowledgments
Daniel Elenius Madsen, Emily K. Waters and Bo Wiinberg are employees at Novo Nordisk A/
S. The employment did not pose a conflict or bias. Novo Nordisk A/S provided support in the
form of salaries for authors [DEM, EKW and BW], but did not have any additional role in the
study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Timothy C. Nichols received unrestricted funding for some of this work from Novo Nor-
disk A/S and has received other research funds from Novo Nordisk A/S, but none of this fund-
ing constitutes a conflict of interest with the data presented in the manuscript.
Elizabeth P. Merricks: no conflict of interest.
Coagulation factor VIII/IX sensitive thrombin generation test for canine plasma
PLOS ONE | https://doi.org/10.1371/journal.pone.0175030 April 6, 2017 14 / 16
Author Contributions
Conceptualization: DEM TCN EPM EKW BW.
Data curation: DEM.
Formal analysis: DEM TCN EPM EKW BW.
Funding acquisition: BW DEM.
Investigation: DEM TCN EPM EKW BW.
Methodology: DEM TCN EPM EKW BW.
Project administration: DEM BW.
Resources: DEM TCN EPM.
Supervision: TCN BW.
Validation: DEM TCN EPM EKW BW.
Visualization: DEM.
Writing – original draft: DEM TCN EPM EKW BW.
References
1. Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare
Dis. 2012; 7:24. PubMed Central PMCID: PMCPMC3502605. https://doi.org/10.1186/1750-1172-7-24
PMID: 22551339
2. White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, et al. Definitions in
hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific
and standardization committee of the International Society on Thrombosis and Haemostasis. Thrombo-
sis and haemostasis. 2001; 85(3):560. PMID: 11307831
3. Den Uijl IE, Mauser Bunschoten EP, Roosendaal G, Schutgens RE, Biesma DH, Grobbee DE, et al.
Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia: the offi-
cial journal of the World Federation of Hemophilia. 2011; 17(6):849–53.
4. Kempton CL, Meeks SL. Toward optimal therapy for inhibitors in hemophilia. Blood. 2014; 124
(23):3365–72. https://doi.org/10.1182/blood-2014-05-577643 PMID: 25428222
5. Berntorp E, Shapiro AD. Modern haemophilia care. The Lancet. 2012; 379(9824):1447–56.
6. Dargaud Y, Negrier C. Thrombin generation testing in haemophilia comprehensive care centres. Hae-
mophilia: the official journal of the World Federation of Hemophilia. 2010; 16(2):223–30.
7. Dargaud Y, Wolberg AS, Luddington R, Regnault V, Spronk H, Baglin T, et al. Evaluation of a standard-
ized protocol for thrombin generation measurement using the calibrated automated thrombogram: an
international multicentre study. Thrombosis research. 2012; 130(6):929–34. https://doi.org/10.1016/j.
thromres.2012.07.017 PMID: 22909826
8. Santagostino E, Mancuso ME, Tripodi A, Chantarangkul V, Clerici M, Garagiola I, et al. Severe hemo-
philia with mild bleeding phenotype: molecular characterization and global coagulation profile. Journal
of thrombosis and haemostasis: JTH. 2010; 8(4):737–43. https://doi.org/10.1111/j.1538-7836.2010.
03767.x PMID: 20102490
9. Luna-Zaizar H, Beltran-Miranda CP, Esparza-Flores MA, Soto-Padilla J, Berges-Garcia A, Rodriguez-
Zepeda MD, et al. Thrombin generation as objective parameter of treatment response in patients with
severe haemophilia A and high-titre inhibitors. Haemophilia: the official journal of the World Federation
of Hemophilia. 2014; 20(1):e7–14.
10. Lozier JN, Nichols TC. Animal models of hemophilia and related bleeding disorders. Seminars in hema-
tology. 2013; 50(2):175–84. PubMed Central PMCID: PMC3742033. https://doi.org/10.1053/j.
seminhematol.2013.03.023 PMID: 23956467
11. Brinkhous KM, Hedner U, Garris JB, Diness V, Read MS. Effect of recombinant factor VIIa on the hemo-
static defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. Proceedings of the
National Academy of Sciences of the United States of America. 1989; 86(4):1382–6. PubMed Central
PMCID: PMC286694. PMID: 2784006
Coagulation factor VIII/IX sensitive thrombin generation test for canine plasma
PLOS ONE | https://doi.org/10.1371/journal.pone.0175030 April 6, 2017 15 / 16
12. von Drygalski A, Cramer TJ, Bhat V, Griffin JH, Gale AJ, Mosnier LO. Improved hemostasis in hemo-
philia mice by means of an engineered factor Va mutant. Journal of thrombosis and haemostasis: JTH.
2014; 12(3):363–72. PubMed Central PMCID: PMC4161283. https://doi.org/10.1111/jth.12489 PMID:
24818532
13. Hansson KM, Lindblom A, Elg M, Lovgren A. Recombinant human prothrombin (MEDI8111) prevents
bleeding in haemophilia A and B mice. Haemophilia: the official journal of the World Federation of
Hemophilia. 2015.
14. Lozier JN, Dutra A, Pak E, Zhou N, Zheng Z, Nichols TC, et al. The Chapel Hill hemophilia A dog colony
exhibits a factor VIII gene inversion. Proceedings of the National Academy of Sciences of the United
States of America. 2002; 99(20):12991–6. PubMed Central PMCID: PMC130574. https://doi.org/10.
1073/pnas.192219599 PMID: 12242334
15. Sabatino DE, Nichols TC, Merricks E, Bellinger DA, Herzog RW, Monahan PE. Animal models of hemo-
philia. Prog Mol Biol Transl Sci. 2012; 105:151–209. PubMed Central PMCID: PMCPMC3713797.
https://doi.org/10.1016/B978-0-12-394596-9.00006-8 PMID: 22137432
16. Evans JP, Brinkhous KM, Brayer GD, Reisner HM, High KA. Canine hemophilia B resulting from a point
mutation with unusual consequences. Proceedings of the National Academy of Sciences of the United
States of America. 1989; 86(24):10095–9. PubMed Central PMCID: PMCPMC298651. PMID: 2481310
17. Sabatino DE, Freguia CF, Toso R, Santos A, Merricks EP, Kazazian HH Jr., et al. Recombinant canine
B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model.
Blood. 2009; 114(20):4562–5. PubMed Central PMCID: PMC2925478. https://doi.org/10.1182/blood-
2009-05-220327 PMID: 19770361
18. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, et al. Calibrated automated
thrombin generation measurement in clotting plasma. Pathophysiology of haemostasis and thrombosis.
2003; 33(1):4–15. https://doi.org/71636 PMID: 12853707
19. Beltran-Miranda CP, Khan A, Jaloma-Cruz AR, Laffan MA. Thrombin generation and phenotypic corre-
lation in haemophilia A. Haemophilia: the official journal of the World Federation of Hemophilia. 2005;
11(4):326–34.
20. Sehgal A, Barros S, Ivanciu L, Cooley B, Qin J, Racie T, et al. An RNAi therapeutic targeting antithrom-
bin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med. 2015; 21
(5):492–7. https://doi.org/10.1038/nm.3847 PMID: 25849132
Coagulation factor VIII/IX sensitive thrombin generation test for canine plasma
PLOS ONE | https://doi.org/10.1371/journal.pone.0175030 April 6, 2017 16 / 16
